KRYSKrystal Biotech, Inc.
$331.81+103% 1Y
$331.81
$161.1552 weeks$371.35
The financials
Krystal Biotech, Inc. by the numbers
Krystal Biotech, Inc. (KRYS) reported revenue of $119M in Q2 2026 (quarter ended Jun 30, 2026), up 24% from the same quarter a year earlier. That came with net income of $55M (46% of revenue). For the full year FY2025, revenue was $389M (+34% year on year) and net income $205M. Its largest region in Q2 2026 was United States at $92M, 77% of the disclosed total, well ahead of Europe at 16%. The next results filing is expected around Nov 2, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $119M | $96M | +24% |
| Operating income | $58M | $39M | +48% |
| Net income | $55M | $38M | +43% |
| Diluted EPS | $1.79 | $1.29 | +39% |
| Geographic | Revenue | Share |
|---|---|---|
| United States | $92M | 77% |
| Europe | $19M | 16% |
| Japan | $8.3M | 7.0% |
Business segments
Revenue split by geographic segment, from SEC XBRL filings.
Latest period: Q2 2026Total $119.2M (+2.5%)
Segment Latestquarter on quarteryear on year
- United States$91.6M$91.6Mquarter on quarter +4.7%year on year -4.6%+4.7%-4.6%
- Europe$19.3M$19.3Mquarter on quarter -6.7%year on year n/a-6.7%n/a
- Japan$8.3M$8.3Mquarter on quarter +1.4%year on year n/a+1.4%n/a
On our screens:Most shorted stocks